Albumin coated cadmium nanoparticles as chemotherapeutic agent against MDA-MB 231 human breast cancer cell line
Source abstract
Abstract
With the aim of dedicating toxicity of cadmium nanoparticles (CdNPs) against invasive breast cancer, with minimum damage to surrounding healthy cells, CdNPs were coated with albumin nanocarrier by nanoprecipitation method and named CdNPs@BSA. The characterization was done by TEM image, DLS and UV-Vis, fluorescence, circular dichroism spectroscopy. The cytotoxic efficacy of the CdNPs@BSA against human breast cancer cells (MDA-MB 231 cells) was examined by MTT assay. Apoptosis, as the mechanism of cell death, was verified by inverted microscopy, fluorescent microscopy, gel electrophoresis and flow cytometry. The role of ROS generation in apoptosis was also studied. It was found that the resulted CdNPs@BSA (diameter of 88 nm and zeta potential of about -18.85 mV) was suitable for penetration in tumour micro vessels. In the form of CdNPs@BSA, the 77% of the secondary structure and almost all of the tertiary structure remain intact. Comparing to CdNPs, CdNPs@BSA could significantly suppress the MDA-MB 231 while they were less toxic on WBCs. Therefore, they could be a brilliant candidate to be used as a chemotherapeutic agent against invasive breast cancer cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Gold and Silver Nanoparticles Synthesis and Applications · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Biochemistry and Biophysics (IBB), University of Tehran
Nanobiomedicine Center of Excellence, Nanoscience and Nanotechnology Research Center, University of Tehran
Biological Sciences, Faculty of New Science and Technology, University of Tehran
References (55)
Show source-provided references
1. 10.1080/21691401.2016.127692310.1080/21691401.2016.1276923 ↗
2. 10.1007/BF0180378410.1007/BF01803784 ↗
3. 10.1080/0020745060059201610.1080/00207450600592016 ↗
4. 10.1517/14740338.1.3.25310.1517/14740338.1.3.253 ↗
5. 10.1080/0895837070147932310.1080/08958370701479323 ↗
6. 10.1016/j.tox.2013.02.01010.1016/j.tox.2013.02.010 ↗
7. 10.1016/j.taap.2009.04.01010.1016/j.taap.2009.04.010 ↗
8. 10.3109/1071754960902946210.3109/10717549609029462 ↗
9. Azizi M, Ghourchian H, Yazdian F, et al. Anticancer and antioxidant properties of Ag NPs coated with BSA NPs. Iran J Chem Eng. 2015;12:23.
10. Das S, Banerjee R, Bellare J. Aspirin loaded albumin nanoparticles by coacervation: implications in drug delivery. Trends Biomater Artif Organs. 2005;18:203–212.
11. 10.1208/s12248-012-9339-410.1208/s12248-012-9339-4 ↗
12. 10.1016/j.jconrel.2011.07.03110.1016/j.jconrel.2011.07.031 ↗
13. 10.1186/1758-5996-3-1110.1186/1758-5996-3-11 ↗
14. 10.1038/s41598-017-05461-310.1038/s41598-017-05461-3 ↗
15. Babson AL, Winnick T. Protein transfer in tumor-bearing rats. Cancer Res. 1954;14:606–611.
16. 10.1016/S1040-8428(97)00015-210.1016/S1040-8428(97)00015-2 ↗
17. 10.1016/j.ijpharm.2004.08.01510.1016/j.ijpharm.2004.08.015 ↗
18. 10.1158/1535-7163.MCT-07-238410.1158/1535-7163.MCT-07-2384 ↗
19. 10.1371/journal.pone.018863910.1371/journal.pone.0188639 ↗
20. 10.3109/21691401.2014.99883010.3109/21691401.2014.998830 ↗
21. 10.7150/thno.719310.7150/thno.7193 ↗
22. 10.1016/j.clbc.2011.03.00710.1016/j.clbc.2011.03.007 ↗
23. 10.3329/dujps.v12i1.1629710.3329/dujps.v12i1.16297 ↗
24. Desai NP Tao C Yang A et al. Protein stabilized pharmacologically active agents methods for the preparation thereof and methods for the use thereof. Google Patents; 2004.
25. 10.1038/srep2650810.1038/srep26508 ↗
26. 10.1080/07391102.2016.122297210.1080/07391102.2016.1222972 ↗
27. 10.3109/10731199.2011.58105210.3109/10731199.2011.581052 ↗
28. 10.1080/21691401.2016.126363910.1080/21691401.2016.1263639 ↗
29. 10.1016/S0889-8588(18)30099-610.1016/S0889-8588(18)30099-6 ↗
30. 10.1016/j.colsurfb.2013.01.02710.1016/j.colsurfb.2013.01.027 ↗
31. 10.1016/0167-5699(93)90214-610.1016/0167-5699(93)90214-6 ↗
32. 10.1007/s00210-014-1038-510.1007/s00210-014-1038-5 ↗
33. 10.1101/pdb.prot442910.1101/pdb.prot4429 ↗
34. 10.1016/j.jcis.2014.07.01310.1016/j.jcis.2014.07.013 ↗
35. Shapiro HM. Practical flow cytometry. Hoboken, NJ, USA: John Wiley & Sons; 2005.
36. 10.1021/tx00026a01210.1021/tx00026a012 ↗
37. 10.1016/j.jconrel.2008.05.01010.1016/j.jconrel.2008.05.010 ↗
38. 10.2217/nnm.11.14110.2217/nnm.11.141 ↗
39. 10.1073/pnas.95.8.460710.1073/pnas.95.8.4607 ↗
40. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752–3756.
41. 10.1016/j.jeurceramsoc.2011.08.01510.1016/j.jeurceramsoc.2011.08.015 ↗
42. 10.1039/dc990900030110.1039/dc9909000301 ↗
43. 10.1021/jp100903x10.1021/jp100903x ↗
44. 10.1021/jf025678810.1021/jf0256788 ↗
45. 10.3109/21691401.2014.94245610.3109/21691401.2014.942456 ↗
46. 10.1146/annurev.physchem.58.032806.10460710.1146/annurev.physchem.58.032806.104607 ↗
47. 10.1039/c2pp25222h10.1039/c2pp25222h ↗
48. 10.1021/la063627p10.1021/la063627p ↗
49. 10.1002/cphc.20130031310.1002/cphc.201300313 ↗
50. 10.1074/jbc.272.41.2596810.1074/jbc.272.41.25968 ↗
51. 10.1038/284555a010.1038/284555a0 ↗
52. 10.1097/IGC.000000000000010510.1097/IGC.0000000000000105 ↗
53. 10.4161/cc.7.11.598210.4161/cc.7.11.5982 ↗
54. 10.1074/jbc.R109.02382010.1074/jbc.R109.023820 ↗
55. 10.1016/j.chemosphere.2015.08.02010.1016/j.chemosphere.2015.08.020 ↗